Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients

Journal of the Egyptian National Cancer Institute
Alaa Mohamed MariaYomna Zamzam

Abstract

The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study. Immunohistochemistry (IHC) method was used to analyze p95-HER2 expression in the formalin-fixed, paraffin-embedded (FFPE) blocks of the enrolled patients. p95-HER2 was positive in 34.4% of the patients. The median overall survival (OS) was 22.5 and 35 months for p95-HER2 positive and negative patients, respectively (p = 0.036) and the median time to metastases was 14 and 21 months, respectively (p = 0.006). There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p = 0.004), high Ki-67 expression (p < 0.001) and development of visceral metastasis (p = 0.034). Expression of p95-HER2 in HER2-positive BC patients is significantly associated with negative hormonal receptors express...Continue Reading

References

Oct 7, 2003·Molecular Cell·Antony W BurgessShigeyuki Yokoyama
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L SpectorSarah Bacus
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rosana SáezGail M Clinton
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry L GomezGeorge W Sledge
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Spector, Kimberly L Blackwell
Apr 22, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maurizio ScaltritiJosé Baselga
Jul 29, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeff SperindeAllan Lipton
Aug 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joaquín ArribasKim Pedersen
Feb 24, 2011·Expert Review of Anticancer Therapy·Devika Gajria, Sarat Chandarlapaty
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Mar 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Renata DuchnowskaJacek Jassem
Aug 20, 2015·Breast Cancer Research : BCR·Galatea KallergiVassilis Georgoulias
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Piccart-GebhartEdith A Perez
Nov 29, 2015·Seminars in Oncology·Elisa ZanardiSerena Di Cosimo
Apr 26, 2017·World Journal of Clinical Oncology·Viviana Masoud, Gilles Pagès

❮ Previous
Next ❯

Citations

Nov 21, 2020·Annals of the New York Academy of Sciences·Yueping LiuYingyong Hou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.